Triveni Bio Stock
HealthTechLooking to sell Triveni Bio stock or options?
Triveni Bio has developed a drug discovery platform focused on creating targeted therapies for immune and inflammatory (I&I) disorders. Utilizing a genetics-informed methodology, the company identifies patients who are most likely to benefit from their treatments, enhancing precision and minimizing trial and error. This approach helps in advancing the development of novel therapies that are more effective and less toxic than existing options, ultimately providing patients with improved treatment outcomes.
Deep Track Capital, Polaris Partners, Goldman Sachs Asset Management, Borealis Ventures, Fidelity Management & Research, Magnetic Ventures, OrbiMed, Cormorant Asset Management, Viking Global Investors, The Invus Group, Atlas Venture, Alexandria Venture Investments.